Atlas Trials

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Clinical trial NCT06953882 · RECRUITING

Trial details

NCT number
NCT06953882
Sponsor
Yale University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2 Negative Breast Cancer
Start date
2025-07-09
Primary completion
2030-09-01
Enrollment
140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.